stoxline Quote Chart Rank Option Currency Glossary
  
ORIC Pharmaceuticals, Inc. (ORIC)
7.73  0.08 (1.05%)    11-19 15:31
Open: 7.86
High: 7.97
Volume: 608,471
  
Pre. Close: 7.65
Low: 7.58
Market Cap: 803(M)
Technical analysis
2026-11-19 3:16:39 PM
Short term     
Mid term     
Targets 6-month :  13.67 1-year :  16.71
Resists First :  11.7 Second :  14.31
Pivot price 8.59
Supports First :  7.5 Second :  6.24
MAs MA(5) :  7.75 MA(20) :  8.91
MA(100) :  11.74 MA(250) :  10.77
MACD MACD :  -1.1 Signal :  -1
%K %D K(14,3) :  11.1 D(3) :  8.7
RSI RSI(14): 33.8
52-week High :  14.68 Low :  7.23
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ORIC ] has closed above bottom band by 17.4%. Bollinger Bands are 15.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.06 - 8.11 8.11 - 8.14
Low: 7.42 - 7.48 7.48 - 7.53
Close: 7.56 - 7.65 7.65 - 7.72
Company Description

ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.

Headline News

Thu, 19 Nov 2026
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Target Lowered at HC Wainwright - MarketBeat

Tue, 17 Nov 2026
ORIC Pharmaceuticals, Inc. reports results for the quarter ended September 30 - Earnings Summary - TradingView

Tue, 17 Nov 2026
Oric Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $22.31, Implies 197% Upside - TradingView

Tue, 17 Nov 2026
ORIC Pharmaceuticals, Inc. (ORIC) stock price, news, quote and history - Yahoo Finance UK

Tue, 17 Nov 2026
ORIC Pharmaceuticals, Inc. (ORIC) Stock Price, News, Quote & History - Yahoo! Finance Canada

Mon, 16 Nov 2026
ORIC Pharmaceuticals, Inc. (ORIC) stock price, news, quote and history - Yahoo Finance Australia

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 104 (M)
Shares Float 89 (M)
Held by Insiders 1.5 (%)
Held by Institutions 123 (%)
Shares Short 15,420 (K)
Shares Short P.Month 17,530 (K)
Stock Financials
EPS -1.33
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.68
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -26 %
Return on Equity (ttm) -39.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.5
Qtrly Earnings Growth 0 %
Operating Cash Flow -112 (M)
Levered Free Cash Flow -69 (M)
Stock Valuations
PE Ratio -5.86
PEG Ratio 0
Price to Book value 2.1
Price to Sales 0
Price to Cash Flow -7.18
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

Stoxline iOS

Alpha Bridge iOS

OptionCalc iOS

StockChart Android

Stoxline Android

Alpha Bridge Android

OptionCalc Android